epipen
-
FDA Rejects ARS Pharma’s Nasal Spray Alternative to Injectable Epinephrine
ARS Pharmaceuticals frames its intranasal epinephrine spray as a needle-free alternative to products such as EpiPen. Though this spray won the backing of an FDA advisory committee, the agency is now requiring that ARS Pharma run another study to support a regulatory submission.
-
EpiPen, often chided for high price, gets first generic competitor
The drugmaker’s generic had originally met with FDA rejection in early 2016, amid a national debate over EpiPen’s price.
-
Payer’s Place: Dawn Maroney
Dawn Maroney, President, Markets of Alignment Health and CEO of Alignment Health Plan, to discuss how they are using technology to provide better service and care to consumers.
-
Why did Mylan invest in coal plants?
Mylan evidently subscribes to a “living in the gray” mentality when it comes to business operations.
-
Is Mylan’s EpiPen reign finally over?
A healthy dose of competition has been injected into the market for life-saving emergency epinephrine injectors.
-
Mylan settles EpiPen Medicaid rebate case for $465M, stock jumps
Mylan settled with the U.S. Department of Justice to head off potential Medicaid liability claims by federal and state governments.
-
Runaway cost of EpiPens hits taxpayers right in their Medicare
The abrupt rise is notable because many people think that life-threatening allergies are less common among the elderly. In addition, epinephrine — the active ingredient in EpiPens — can pose greater risks to older adults.
-
Jimmy Kimmel disses EpiPen during Emmy Awards
Jimmy Kimmel makes a timely joke about EpiPen during the 68th Annual Emmy Awards he was hosting Sunday night.
-
How Mylan cornered the consumer epinephrine market
High-profile deaths in several states have helped to spur legislative action and fuel demand for consumer-dispensed epinephrine. At the same time, no other company has been able to effectively compete with Mylan’s EpiPen.
-
EpiPen is just tip of the iceberg for FDA generic drug backlog
Critics say getting generic alternatives to the U.S. market for products like EpiPen is still taking far too long.
-
Applying Remote Patient Monitoring to Surgery Prep and Recovery, Oncology and Women’s Health
Join us to learn about the latest trends in remote monitoring and how to extend its benefits beyond chronic conditions to more patients – all while using fewer staff resources.
-
Five most-read stories of the week
From Apple’s acquisition of Gliimpse to the story behind Bristol-Myers Squibb’s failed Opdivo immunotherapy drug, here were the most-read stories of the week.
-
Now, the gloves are off in the EpiPen saga
The maker of EpiPen, the life-saving auto-injector for anaphylaxis, is under fire for exorbitant price hikes so much so that even Martin Shkreli called Mylan out for price-gouging last week.
-
Windgap Medical – making progress toward an alternative to the EpiPen
Windgap Medical is moving forward in its development of its EpiPen alternative device with two newly solidified patents.
-
Top Story, Devices & Diagnostics
Innovation is in progress to replace the bulky EpiPen with something more practical
There must be some better, more efficient solutions for the essential use of the EpiPen, and Windgap Medical is working on it.
Promoted
Payer’s Place: Dr. Anil Singh
Dr. Anil Singh shares his insights into the strategies employed by the organization to identify the most effective digital solutions for their members.
Promoted
Discover the Next-Gen Platform for Integrated Collaborative Care
Beyond EHRs and digital front doors, reducing the gaps in patient care journeys.
